Disease Progression and Mutation Pattern in a Large Cohort of LGMD R1/LGMD 2A Patients from India

Abstract

Calpainopathy is caused by mutations in the CAPN3. There is only one clinical and genetic study of CAPN3 from India and none from South India. A total of 72 (male[M]:female [F] = 34:38) genetically confirmed probands from 72 independent families are included in this study. Consanguinity was present in 54.2%. The mean age of onset and duration of symptoms are 13.5 ± 6.4 and 6.3 ± 4.7 years, respectively. Positive family history occurred in 23.3%. The predominant initial symptoms were proximal lower limb weakness (52.1%) and toe walking (20.5%). At presentation, 97.2% had hip girdle weakness, 69.4% had scapular winging, and 58.3% had contractures. Follow-up was available in 76.4%, and 92.7% were ambulant at a mean age of 23.7 ± 7.6 years and duration of 4.5 years, remaining 7.3% became wheelchair-bound at 25.5 ± 5.7 years of age (mean duration = 13.5 ± 4.6), 4.1% were aged more than 40 years (duration range = 5-20). The majority remained ambulant 10 years after disease onset. Next-generation sequencing (NGS) detected 47 unique CAPN3 variants in 72 patients, out of which 19 are novel. Missense variants were most common occurring in 59.7% (homozygous = 29; Compound heterozygous = 14). In the remaining 29 patients (40.3%), at least one suspected loss of function variant was present. Common recurrent variants were c.2051-1G > T and c.2338G > C in 9.7%, c.1343G > A, c.802-9G > A, and c.1319G > A in 6.9% and c.1963delC in 5.5% of population. Large deletions were observed in 4.2%. Exon 10 mutations accounted for 12 patients (16.7%). Our study highlights the efficiency of NGS technology in screening and molecular diagnosis of limb-girdle muscular dystrophy with recessive form (LGMDR1) patients in India.

Keywords

CAPN3 / muscular dystrophy / LGMDR1 / next-generation sequencing

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

None.

Conflict of Interest

None declared.

Acknowledgments

The authors thank the patients and their families for participating in this study.

References

[1] Dinçer P, Leturcq F, Richard I.et al.A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol 1997; 42(02): 222-229

[2] Martinez-Thompson JM, Niu Z, Tracy JA.et al.Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21. Muscle Nerve 2018; 57(04): 679-683

[3] Vissing J, Barresi R, Witting N.et al.A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016; 139(Pt 8): 2154-2163

[4] Richard I, Broux O, Allamand V.et al.Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81(01): 27-40

[5] Campbell RL, Davies PL.Structure-function relationships in calpains. Biochem J 2012; 447(03): 335-351

[6] Sorimachi H, Hata S, Ono Y.Calpain chronicle-an enzyme family under multidisciplinary characterization. Proc Jpn Acad, Ser B, Phys Biol Sci 2011; 87(06): 287-327

[7] Beckmann JS, Richard I, Hillaire D.et al.A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. C R Acad Sci III 1991; 312(04): 141-148

[8] Sorimachi H, Imajoh-Ohmi S, Emori Y.et al.Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 1989; 264(33): 20106-20111

[9] Kramerova I, Kudryashova E, Tidball JG, Spencer MJ.Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum Mol Genet 2004; 13(13): 1373-1388

[10] Partha SK, Ravulapalli R, Allingham JS, Campbell RL, Davies PL.Crystal structure of calpain-3 penta-EF-hand (PEF) domain - a homodimerized PEF family member with calcium bound at the fifth EF-hand. FEBS J 2014; 281(14): 3138-3149

[11] Chou FL, Angelini C, Daentl D.et al.Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. Neurology 1999; 52(05): 1015-1020

[12] Gómez-Díaz B, Rosas-Vargas H, Roque-Ramírez B.et al.Immunodetection analysis of muscular dystrophies in Mexico. Muscle Nerve 2012; 45(03): 338-345

[13] Moore SA, Shilling CJ, Westra S.et al.Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 2006; 65(10): 995-1003

[14] Pathak P, Sharma MC, Sarkar C.et al.Limb girdle muscular dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and histopathological correlation. Neurol India 2010; 58(04): 549-554

[15] Todorova A, Georgieva B, Tournev I.et al.A large deletion and novel point mutations in the calpain 3 gene (CAPN3) in Bulgarian LGMD2A patients. Neurogenetics 2007; 8(03): 225-229

[16] Balci B, Aurino S, Haliloglu G.et al.Calpain-3 mutations in Turkey. Eur J Pediatr 2006; 165(05): 293-298

[17] Richard I, Brenguier L, Dinçer P.et al.Multiple independent molecular etiology for limb-girdle muscular dystrophy type 2A patients from various geographical origins. Am J Hum Genet 1997; 60(05): 1128-1138

[18] Dadali EL, Shagina OA, Ryzhkova OP, Rudenskaia GE, Fedotov VP, Poliakov AV. [Clinical-genetic characteristics of limb girdle-muscular dystrophy type 2A]. Zh Nevrol Psikhiatr Im S S Korsakova 2010; 110(04): 79-83

[19] Pogoda TV, Krakhmaleva IN, Lipatova NA, Shakhovskaya NI, Shishkin SS, Limborska SA.High incidence of 550delA mutation of CAPN3 in LGMD2 patients from Russia. Hum Mutat 2000; 15(03): 295

[20] Urtasun M, Sáenz A, Roudaut C.et al.Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). Brain 1998; 121(pt. 9): 1735-1747

[21] Renjini R, Gayathri N, Nalini A, Srinivas Bharath MM.Analysis of calpain-3 protein in muscle biopsies of different muscular dystrophies from India. Indian J Med Res 2012; 135(06): 878-886

[22] Nalini A, Polavarapu K, Sunitha B.et al.A prospective study on the immunophenotypic characterization of limb girdle muscular dystrophies 2 in India. Neurol India 2015; 63(04): 548-560

[23] Khadilkar SV, Chaudhari CR, Dastur RS, Gaitonde PS, Yadav JG.Limb-girdle muscular dystrophy in the Agarwals: utility of founder mutations in CAPN3 gene. Ann Indian Acad Neurol 2016; 19(01): 108-111

[24] Pathak P, Sharma MC, Jha P.et al.Mutational Spectrum of CAPN3 with genotype-phenotype correlations in limb girdle muscular dystrophy type 2A/R1 (LGMD2A/LGMDR1) patients in India. J Neuromuscul Dis 2021; 8(01): 125-136

[25] Angelini C, Nardetto L, Borsato C.et al.The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res 2010; 32(01): 41-46

[26] Richard I, Hogrel JY, Stockholm D.et al; Calpainopathy Study Group. Natural history of LGMD2A for delineating outcome measures in clinical trials. Ann Clin Transl Neurol 2016; 3(04): 248-265

[27] Fanin M, Nardetto L, Nascimbeni AC.et al.Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A. J Med Genet 2007; 44(10): 609-614

[28] Vanhoutte EK, Faber CG, van Nes SI. et al; PeriNomS Study Group. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012; 135(Pt 5): 1639-1649

[29] Richards S, Aziz N, Bale S.et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17(05): 405-424

[30] Chae J, Minami N, Jin Y.et al.Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul Disord 2001; 11(6,7): 547-555

[31] Magri F, Nigro V, Angelini C.et al.The italian limb girdle muscular dystrophy registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve 2017; 55(01): 55-68

[32] Sáenz A, Leturcq F, Cobo AM.et al.LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005; 128(pt. 4): 732-742

[33] Fanin M, Angelini C.Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: the yield and the pitfalls. Muscle Nerve 2015; 52(02): 163-173

[34] Peric S, Stevanovic J, Johnson K.et al.Phenotypic and genetic spectrum of patients with limb-girdle muscular dystrophy type 2A from Serbia. Acta Myol 2019; 38(03): 163-171

[35] Fardeau M, Hillaire D, Mignard C.et al.Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996; 119(pt. 1): 295-308

[36] Fanin M, Nascimbeni AC, Angelini C.Muscle atrophy in Limb Girdle Muscular Dystrophy 2A: a morphometric and molecular study. Neuropathol Appl Neurobiol 2013; 39(07): 762-771

[37] Fanin M, Nascimbeni AC, Angelini C.Gender difference in limb-girdle muscular dystrophy: a muscle fiber morphometric study in 101 patients. Clin Neuropathol 2014; 33(03): 179-185

[38] Groen EJ, Charlton R, Barresi R.et al.Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 2007; 130(Pt 12): 3237-3249

[39] Dirik E, Aydin A, Kurul S, Sahin B.Limb girdle muscular dystrophy type 2A presenting with cardiac arrest. Pediatr Neurol 2001; 24(03): 235-237

[40] Piluso G, Politano L, Aurino S.et al.Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005; 42(09): 686-693

[41] de Paula F, Vainzof M, Passos-Bueno MR.et al. Clinical variability in calpainopathy: what makes the difference?. Eur J Hum Genet 2002; 10(12): 825-832

RIGHTS & PERMISSIONS

Global Medical Genetics